New Delhi, June 15 -- The Indian pharmaceutical industry is assessing its supply chain stabilization options following a breakthrough framework agreement between the US and Iran.

The preliminary deal outlines an immediate and permanent end to military operations across all fronts, including Lebanon, signalling a potential conclusion to the 107-day war in West Asia.

For India's $60 billion pharmaceutical sector, the 14-point memorandum of understanding offers a potential reprieve after months of severe operational stress.

The war had restricted maritime transit through the Strait of Hormuz, choking the supply of critical petrochemical inputs. Most notably, the blockade triggered an acute shortage of propylene, a fundamental feedstock fo...